The world watched in horror as Christian Eriksen collapsed on the pitch during Denmark’s Euro 2020 opener. But what followed was a testament to modern medical technology and swift human action. The device that saved his life, a subcutaneous implantable cardioverter-defibrillator (S-ICD), is now being hailed as a blueprint for sport safety.
Developed by Boston Scientific and refined in the UK, the S-ICD is a marvel of miniaturised engineering. It sits under the skin, constantly monitoring heart rhythm and delivering a shock when needed. For Eriksen, that shock came within seconds of his cardiac arrest.
The device was part of a broader emergency protocol that included CPR and a defibrillator, but its role was pivotal. The UK’s National Health Service had already been piloting community access to similar devices, and their success rate in public settings is now over 90 percent. For athletes, the stakes are higher.
Sudden cardiac arrest is the leading cause of death in young athletes, and traditional chest-thumping defibrillators can fail if not applied precisely. The S-ICD eliminates that variable. It learns the heart’s normal rhythm and intervenes only when necessary.
It’s like having a paramedic on call 24/7, minus the wait. The technology isn’t new; it was approved in Europe in 2012. But Eriksen’s case has accelerated its adoption in sport.
FIFA and UEFA are now reviewing protocols for mandatory S-ICD implantation in players with known heart conditions. Critics warn of over-reliance on tech. What about access?
The device costs around £20,000, and implantation requires surgery. But compared to the cost of a lost life or a career-ending collapse, it’s a bargain. The real challenge is equity.
Will every young athlete in grassroots football get the same protection as a Premier League star? Probably not yet. But the Eriksen case has shifted the conversation from ‘if’ to ‘when’.
And that’s a win for medical technology and for the beautiful game.
